Guardant Health's stock fell 5.09% as it crossed below the 5-day SMA amid a generally positive market with the Nasdaq-100 and S&P 500 both up slightly.
The company reported Q4 revenue of $280 million, a 39% year-over-year increase, surpassing expectations and indicating strong demand in oncology and screening tests. Despite a negative free cash flow of approximately $54 million in Q4, Guardant Health maintains about $1.3 billion in cash, showcasing financial resilience. Investors are keenly awaiting the audited financial results for Q4 and the full year 2025, scheduled for February 2026.
This strong revenue performance highlights Guardant Health's solid position in the precision medicine market, although the stock's decline may reflect broader market dynamics or investor profit-taking.
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 109.730
Low
105.00
Averages
124.69
High
155.00
Current: 109.730
Low
105.00
Averages
124.69
High
155.00
Guggenheim
NULL -> Buy
upgrade
$115 -> $135
2026-01-26
New
Reason
Guggenheim
Price Target
$115 -> $135
AI Analysis
2026-01-26
New
upgrade
NULL -> Buy
Reason
Guggenheim raised the firm's price target on Guardant Health to $135 from $115 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Mizuho
NULL -> Outperform
maintain
$120 -> $135
2026-01-09
Reason
Mizuho
Price Target
$120 -> $135
2026-01-09
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Guardant Health to $135 from $120 and keeps an Outperform rating on the shares. The firm updated models in the medical devices and diagnostics group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GH
Unlock Now
Stifel
Buy
maintain
$100 -> $120
2026-01-09
Reason
Stifel
Price Target
$100 -> $120
2026-01-09
maintain
Buy
Reason
Stifel raised the firm's price target on Guardant Health to $120 from $100 and keeps a Buy rating on the shares. Considering the outlook for 2026, the firm believes Guardant is set up to have a solid year of volume and average selling price growth, with publication and reimbursement catalysts that will "keep investors interested," the analyst says.
TD Cowen
Dan Brennan
Buy
maintain
$100 -> $130
2026-01-07
Reason
TD Cowen
Dan Brennan
Price Target
$100 -> $130
2026-01-07
maintain
Buy
Reason
TD Cowen analyst Dan Brennan raised the firm's price target on Guardant Health to $130 from $100 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
